ZEBOV GP Protein (AA 33-637) (His tag)

Produktnummer ABIN6941972

Produktdetails

Target: ZEBOV GP (Zaire Ebola Virus Envelope Glycoprotein (ZEBOV GP))

Protein-Typ: Recombinant

Proteineigenschaft: AA 33-637

Spezies: Ebola Virus

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses ZEBOV GP Protein ist gelabelt mit His tag.

Verwendungszweck: Recombinant Ebolavirus EBOV (subtype Zaire,strain Kikwit-95) Envelope Glycoprotein (GP) protein produced in HEK293 cells. Protein contains a C-terminal 6x His-tag

Spezifität: Recombinant Ebolavirus (subtype Zaire, strain Kikwit-95) Envelope Glycoprotein (GP), comprising amino-acids 33-637. This protein is produced in mammalian cells with greater than 85% purity and incorporates a C-terminal 6x His-tag.

Produktmerkmale: Ebola Virus Envelope Glycoprotein (GP) (Zaire)

Reinheit: >85 %

Anwendungsinformationen

Kommentare:

This Ebola virus envelope glycoprotein (GP) contains both GP1 and GP2, in heterodimeric form. It is derived from the GP sequence (Accession # AAQ55048.1), expressing Ile33 – Asp637, and is fused with a polyhistidine tag at the C-terminus. The total calculated MW of Ebola envelope glycoprotein (GP) is 67kDa. The protein is expressed in HEK293 cells, and DTT-reduced protein migrates as two bands of 21-23kDa (GP2) and 110-120kDa (GP1) in SDS-PAGE

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: PBS pH 7.4

Lagerung: 4 °C

Informationen zur Lagerung: 4°C

Antigendetails

Target: ZEBOV GP (Zaire Ebola Virus Envelope Glycoprotein (ZEBOV GP))

Andere Bezeichnung: Ebola Envelope Glycoprotein (GP) (Zaire) (ZEBOV GP Produkte)

Substanzklasse: Viral Protein

Hintergrund: Ebola hemorrhagic fever (EHF) is a severe disease caused by several species of Ebolavirus (EBOV), in the family Filoviridae. Prior to 2007, four species of EBOV had been identified, with two (Zaire ebolavirus andSudan ebolavirus) having caused significant disease outbreaks in humans. The presence of a fifth EBOV virus species,Bundibugyo ebolavirus (BEBOV) was identified after an outbreak of EHF in the Bundibugyo District of western Uganda in 2007. Outbreaks of EHF are associated with person-to-person transmission after the virus is introduced into humans from a zoonotic reservoir. During outbreaks the virus is commonly transmitted through direct contact with infected persons or their bodily fluids. The onset of EHF is associated with nonspecific signs and symptoms, including fever, myalgias, headache, abdominal pain, nausea, vomiting, and diarrhoea. In the later stages of disease, overt haemorrhage has been reported in up to 50% of cases.
The Zaire subtype of the Ebola virus family is currently the most important in relation to outbreaks of disease in humans. This subtype has been responsible for the largest ever outbreak of EHF, which started in West Africa in 2014, and was finally declared over only in early 2016. The Kikwit-95 strain was isolated from an outbreak occurring in the city of Kikwit in Zaire in 1995. This outbreak has been especially well studied. There were 314 cases, with 244 fatalities, a mortality rate ofGreater than75%.
Ebola virus envelope glycoprotein is initially produced as a precursor known as pre-GP, which is cleaved by furin into two subunits, GP1 and GP2, which remain associated through a disulfide linkage between Cys53 of GP1 and Cys609 of GP2. This heterodimer assembles into a 450-kDa trimer at the surface of nascent virions. The virion-attached GP is critical in the EBOV life cycle, as it is solely responsible for attachment, fusion and entry of target cells. Moreover, GP is responsible for critical pathogenic differences among viral species.

UniProt: AAQ55048.1